Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (REGN)


Statement of Cash Flows

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Regeneron Pharmaceuticals Inc., Consolidated Statement of Cash Flows

USD $ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income 2,444,400  1,198,511  895,522  636,056  348,074 
Depreciation and amortization 148,200  145,467  104,745  74,909  52,686 
Non-cash compensation expense 427,400  507,277  559,878  459,049  307,238 
Other non-cash items, net 12,100  63,581  45,139  52,562  81,524 
Deferred taxes (140,000) 318,809  (360,078) (121,623) (66,604)
(Increase) decrease in Sanofi, Bayer, and trade accounts receivable (268,900) (362,720) (143,827) (491,421) (62,432)
(Increase) decrease in inventories (387,900) (314,195) (149,776) (111,825) (60,900)
(Increase) decrease in prepaid expenses and other assets (55,700) (113,331) 23,543  (79,476) (37,767)
Increase (decrease) in deferred revenue (194,500) (113,099) 244,270  608,892  19,102 
Increase (decrease) in accounts payable, accrued expenses, and other liabilities 210,000  (23,188) 253,980  303,657  162,236 
Changes in assets and liabilities (697,000) (926,533) 228,190  229,827  20,239 
Adjustments to reconcile net income to net cash provided by operating activities (249,300) 108,601  577,874  694,724  395,083 
Net cash provided by operating activities 2,195,100  1,307,112  1,473,396  1,330,780  743,157 
Purchases of marketable and other securities (1,845,500) (1,277,140) (809,419) (557,105) (564,188)
Sales or maturities of marketable securities 775,600  544,584  274,456  327,437  476,417 
Capital expenditures (383,100) (272,626) (511,941) (677,933) (333,006)
Other (10,000) —  —  —  — 
Net cash used in investing activities (1,463,000) (1,005,182) (1,046,904) (907,601) (420,777)
Proceeds in connection with capital and facility lease obligations —  57,000  5,085  27,373  — 
Payments in connection with capital and facility lease obligations —  (19,925) (32,774) (1,353) (1,095)
Repayments of convertible senior notes —  —  (12,894) (166,467) (220,639)
Payments in connection with reduction of outstanding warrants —  —  (643,365) (573,487) (294,552)
Proceeds from issuance of Common Stock 114,500  240,213  126,739  206,358  126,045 
Payments in connection with Common Stock tendered for employee tax obligations (187,200) (301,688) (143,182) (160,537) (267,584)
Repurchases of Common Stock (4,400) —  —  —  — 
Excess tax benefit from stock-based compensation —  —  —  405,317  448,556 
Net cash provided by (used in) financing activities (77,100) (24,400) (700,391) (262,796) (209,269)
Net increase (decrease) in cash, cash equivalents, and restricted cash 655,000  277,530  (273,899) 160,383  113,111 
Cash, cash equivalents, and restricted cash at beginning of period 825,200  535,203  809,102  648,719  535,608 
Cash, cash equivalents, and restricted cash at end of period 1,480,200  812,733  535,203  809,102  648,719 

Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).

Item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Regeneron Pharmaceuticals Inc.’s net cash provided by operating activities declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Regeneron Pharmaceuticals Inc.’s net cash used in investing activities increased from 2016 to 2017 but then declined significantly from 2017 to 2018.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Regeneron Pharmaceuticals Inc.’s net cash provided by (used in) financing activities increased from 2016 to 2017 but then slightly declined from 2017 to 2018.